Compare PDS & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDS | ORIC |
|---|---|---|
| Founded | 1951 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 861.3M |
| IPO Year | 1998 | 2020 |
| Metric | PDS | ORIC |
|---|---|---|
| Price | $89.18 | $8.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $122.33 | $19.73 |
| AVG Volume (30 Days) | 91.8K | ★ 1.0M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | $2.31 | N/A |
| P/E Ratio | $884.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.50 | $7.23 |
| 52 Week High | $103.80 | $14.93 |
| Indicator | PDS | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 39.95 |
| Support Level | $87.74 | $7.83 |
| Resistance Level | $92.40 | $11.22 |
| Average True Range (ATR) | 3.18 | 0.43 |
| MACD | -0.72 | 0.07 |
| Stochastic Oscillator | 5.60 | 48.22 |
Precision Drilling Corp is a provider of contract drilling, completion, and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. The company operates through two industry segments: Contract Drilling Services, which generates maximum revenue and includes drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale, and repair of drilling equipment; and Completion and Production Services, which includes service rigs, oilfield equipment rental, and camp services. The company generates the majority of its revenue from the United States.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.